Zimmer Biomet’s sales grew, but the call was the real show

Not exactly a sleepy orthopedic update

Zimmer Biomet’s second-quarter 2026 earnings call had the kind of headline investors like to see: net sales of $2.177 billion, up 4.8% reported and 4.0% on an organic constant-currency basis. In plain English, that means the business is still moving forward even after you strip out currency noise and other accounting gremlins.

What’s doing the heavy lifting?

The company pointed to growth in hips, specialty businesses, and technology as the engines behind the quarter. That’s important because medtech investors tend to care less about one flashy quarter and more about whether the growth is broad enough to look real instead of just a one-off blip.

Why you should care

If you own ZBH, this is the sort of update that can keep the story from getting stale. A solid sales print suggests demand is holding up, which matters in a sector where execution and procedure volumes can make or break sentiment. It also hints that Zimmer Biomet may have some room to flex its mix toward higher-value offerings instead of just relying on the same old knee-and-hip treadmill.

Big picture: the company isn’t screaming from the rooftops, but it is doing enough to keep investors interested — and in healthcare, sometimes “steady and growing” is the whole game.